Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Thompson AJ, et al. Among authors: sorensen ps. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Lancet Neurol. 2018. PMID: 29275977 Review.
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis Study Group. Sorensen PS, et al. Lancet. 2003 Oct 11;362(9391):1184-91. doi: 10.1016/S0140-6736(03)14541-2. Lancet. 2003. PMID: 14568740 Clinical Trial.
Multiple sclerosis: pathophysiology revisited.
Sorensen PS. Sorensen PS. Lancet Neurol. 2005 Jan;4(1):9-10. doi: 10.1016/S1474-4422(04)00948-2. Lancet Neurol. 2005. PMID: 15620850 Review. No abstract available.
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Roxburgh RH, et al. Among authors: sorensen ps. Neurology. 2005 Apr 12;64(7):1144-51. doi: 10.1212/01.WNL.0000156155.19270.F8. Neurology. 2005. PMID: 15824338
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Frohman EM, et al. Among authors: sorensen ps. Arch Neurol. 2005 Oct;62(10):1519-30. doi: 10.1001/archneur.62.10.1519. Arch Neurol. 2005. PMID: 16216934 Review.
Remyelination is extensive in a subset of multiple sclerosis patients.
Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Brück W, Lucchinetti C, Lassmann H. Patrikios P, et al. Among authors: sorensen ps. Brain. 2006 Dec;129(Pt 12):3165-72. doi: 10.1093/brain/awl217. Epub 2006 Aug 18. Brain. 2006. PMID: 16921173
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. Hartung HP, et al. Among authors: sorensen ps. J Neurol. 2007 Jul;254(7):827-37. doi: 10.1007/s00415-006-0486-3. Epub 2007 Apr 24. J Neurol. 2007. PMID: 17457510 Review.
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS; European NABINMS Consortium. Farrell R, et al. Among authors: sorensen ps. J Int Med Res. 2008 Jan-Feb;36(1):204-8; author reply 208-10. J Int Med Res. 2008. PMID: 18230281 No abstract available.
391 results